Jan 5 (Reuters) - eFFECTOR Therapeutics Inc EFTR.O :
* EFFECTOR THERAPEUTICS PROVIDES POSITIVE CLINICAL DATA
UPDATE FOR
ZOTATIFIN AND GENERAL CORPORATE UPDATE
* EFFECTOR THERAPEUTICS INC - ZOTATIFIN CONTINUES TO SHOW
FAVORABLE ACTIVITY PROFILE
* EFFECTOR THERAPEUTICS INC - EFFECTOR TO FOCUS ON
FRONT-LINE
PD-L1 ≥ 50% COHORT OF KICKSTART TRIAL WITH TOMIVOSERTIB IN
NON-SMALL CELL LUNG CANCER
* EFFECTOR THERAPEUTICS INC - COMPLETED ENROLLMENT IN THIRD
AND
FINAL COHORT IN OUR PHASE 1B STUDY WITH ZOTATIFIN IN COVID-19
Source text for Eikon: ID:nGNX7vRSNK
Further company coverage: EFTR.O
((Reuters.Briefs@thomsonreuters.com;;))